{"id":"zostavax","rwe":[{"pmid":"41910420","year":"2026","title":"Comparative Effectiveness of Recombinant Zoster and Live Attenuated Zoster Vaccines in Chronic Inflammatory Skin Diseases: A Retrospective Cohort Study.","finding":"","journal":"Journal of medical virology","studyType":"Clinical Study"},{"pmid":"41836684","year":"2026","title":"Blistering Eruption on the Subcontinent: The Looming Public Health Threat of Herpes Zoster, 'Shingles' in India and the Urgent need for Vaccination.","finding":"","journal":"Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine","studyType":"Clinical Study"},{"pmid":"41742112","year":"2026","title":"Towards personalized vaccine repurposing for Alzheimer's prevention: genotype-specific protective association of the shingles vaccine with odds of Alzheimer's disease in participants of two large cohort studies.","finding":"","journal":"BMC neurology","studyType":"Clinical Study"},{"pmid":"41734838","year":"2026","title":"A self-assembling ferritin nanoparticle-based trivalent vaccine of gB/gE/gH elicits potent immune responses against varicella-zoster virus.","finding":"","journal":"International journal of biological macromolecules","studyType":"Clinical Study"},{"pmid":"41435736","year":"2026","title":"Disparities in uptake of Shingrix® vaccine in immunosuppressed individuals in England: a population-based cohort study.","finding":"","journal":"Vaccine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Merck Sharp & Dohme LLC","category":"company"}],"phase":"marketed","safety":{},"trials":[],"aliases":["V211","Voster vaccine live","Zoster Vaccine Live","Zoster vaccine","shingles vaccine"],"company":"Merck Sharp & Dohme LLC","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ZOSTAVAX™","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:32:16.510058+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:32:22.357702+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ZOSTAVAX™","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:32:22.567991+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6068357/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:32:23.254236+00:00"}},"allNames":["zostavax™"],"offLabel":[],"synonyms":[],"timeline":[],"aiSummary":"Zostavax is a vaccine developed by Merck Sharp & Dohme LLC to prevent shingles, a painful rash caused by the reactivation of the varicella-zoster virus. It is a live, attenuated vaccine administered via injection. The commercial status of Zostavax is patented, and it is not yet off-patent. Key safety considerations include the risk of herpes zoster, postherpetic neuralgia, and other adverse reactions. Zostavax is approved for use in individuals 50 years of age and older.","approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Zostavax contains a live, attenuated Oka/Merck strain of the varicella-zoster virus, which is administered via subcutaneous injection to stimulate a cell-mediated immune response and provide protection against herpes zoster."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=zostavax%E2%84%A2","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=zostavax™","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:30:25.784743","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:32:24.894321+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"zostavax™","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01911065","phase":"PHASE4","title":"T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":["Herpes Zoster"],"enrollment":54,"completionDate":"2011-12"},{"nctId":"NCT01600079","phase":"","title":"ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-05-15","conditions":["Herpes Zoster","Shingles"],"enrollment":1505647,"completionDate":"2020-10-16"},{"nctId":"NCT02045836","phase":"PHASE3","title":"Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-03-05","conditions":["Herpes Zoster","Herpes Zoster Vaccine"],"enrollment":865,"completionDate":"2016-06-17"},{"nctId":"NCT02519855","phase":"PHASE3","title":"Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-11","conditions":["Herpes Zoster"],"enrollment":882,"completionDate":"2016-01-26"},{"nctId":"NCT01527370","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-31","conditions":["Herpes Zoster","Shingles"],"enrollment":250,"completionDate":"2013-04-09"},{"nctId":"NCT01954251","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-03","conditions":["Herpes Zoster"],"enrollment":829,"completionDate":"2015-03-20"},{"nctId":"NCT02958345","phase":"PHASE4","title":"Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™","status":"COMPLETED","sponsor":"Tulane University","startDate":"2013-06","conditions":["Herpes Zoster","Fibrosis"],"enrollment":28,"completionDate":"2015-07"},{"nctId":"NCT00550745","phase":"PHASE4","title":"ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":["Herpes Zoster"],"enrollment":11999,"completionDate":"2009-01"},{"nctId":"NCT00546819","phase":"PHASE2","title":"ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":["Herpes Zoster"],"enrollment":309,"completionDate":"2010-08"},{"nctId":"NCT01505647","phase":"PHASE3","title":"Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-04","conditions":["Herpes Zoster","Shingles"],"enrollment":498,"completionDate":"2012-11"},{"nctId":"NCT01556451","phase":"PHASE4","title":"ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-04","conditions":["Herpes Zoster","Shingles"],"enrollment":180,"completionDate":"2012-10"},{"nctId":"NCT01245751","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04","conditions":["Herpes Zoster","Varicella-zoster Vaccine"],"enrollment":600,"completionDate":"2015-05"},{"nctId":"NCT00534248","phase":"PHASE3","title":"Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10","conditions":["Shingles"],"enrollment":22439,"completionDate":"2010-01"},{"nctId":"NCT00535730","phase":"PHASE3","title":"ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06","conditions":["Herpes Zoster","Pneumococcal Infection"],"enrollment":473,"completionDate":"2008-02"},{"nctId":"NCT01385566","phase":"PHASE1","title":"A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09","conditions":["Herpes Zoster"],"enrollment":223,"completionDate":"2013-05"},{"nctId":"NCT00886613","phase":"PHASE1","title":"A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":["Herpes Zoster"],"enrollment":120,"completionDate":"2009-12"},{"nctId":"NCT00231816","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-09","conditions":["Herpes Zoster"],"enrollment":763,"completionDate":"2006-03"},{"nctId":"NCT00130793","phase":"PHASE3","title":"A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":["Herpes Zoster"],"enrollment":368,"completionDate":"2005-11"},{"nctId":"NCT00322231","phase":"PHASE3","title":"A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":["Herpes Zoster"],"enrollment":101,"completionDate":"2007-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL6068357"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Merck Sharp & Dohme LLC","relationship":"Original Developer"}],"publicationCount":201,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Merck Sharp & Dohme LLC","recentPublications":[{"date":"2026 Apr","pmid":"41910420","title":"Comparative Effectiveness of Recombinant Zoster and Live Attenuated Zoster Vaccines in Chronic Inflammatory Skin Diseases: A Retrospective Cohort Study.","journal":"Journal of medical virology"},{"date":"2026 Jan-Feb","pmid":"41836684","title":"Blistering Eruption on the Subcontinent: The Looming Public Health Threat of Herpes Zoster, 'Shingles' in India and the Urgent need for Vaccination.","journal":"Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine"},{"date":"2026 Feb 25","pmid":"41742112","title":"Towards personalized vaccine repurposing for Alzheimer's prevention: genotype-specific protective association of the shingles vaccine with odds of Alzheimer's disease in participants of two large cohort studies.","journal":"BMC neurology"},{"date":"2026 Mar","pmid":"41734838","title":"A self-assembling ferritin nanoparticle-based trivalent vaccine of gB/gE/gH elicits potent immune responses against varicella-zoster virus.","journal":"International journal of biological macromolecules"},{"date":"2026 Feb 6","pmid":"41435736","title":"Disparities in uptake of Shingrix® vaccine in immunosuppressed individuals in England: a population-based cohort study.","journal":"Vaccine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ZOSTAVAX™","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:32:24.894321+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}